Q2 2024 EPS Estimates for Janux Therapeutics, Inc. Cut by William Blair (NASDAQ:JANX)

Janux Therapeutics, Inc. (NASDAQ:JANX) – Stock analysts at William Blair reduced their Q2 2024 earnings estimates for shares of Janux Therapeutics in a research note issued on Tuesday, May 7th. William Blair analyst M. Phipps now expects that the company will earn ($0.21) per share for the quarter, down from their prior estimate of ($0.20). William Blair has a “Outperform” rating on the stock. The consensus estimate for Janux Therapeutics’ current full-year earnings is ($1.41) per share. William Blair also issued estimates for Janux Therapeutics’ Q3 2024 earnings at ($0.23) EPS, FY2024 earnings at ($0.97) EPS, Q2 2025 earnings at ($0.25) EPS, FY2025 earnings at ($1.00) EPS, FY2026 earnings at ($1.29) EPS, FY2027 earnings at ($2.12) EPS and FY2028 earnings at ($1.30) EPS.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Friday, March 8th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.12. The business had revenue of $2.46 million for the quarter, compared to analyst estimates of $0.98 million. Janux Therapeutics had a negative net margin of 721.18% and a negative return on equity of 17.88%.

A number of other analysts also recently issued reports on JANX. Jonestrading assumed coverage on shares of Janux Therapeutics in a research report on Tuesday, April 16th. They set a “buy” rating and a $70.00 target price for the company. BTIG Research assumed coverage on shares of Janux Therapeutics in a research report on Thursday, March 21st. They set a “buy” rating and a $62.00 target price for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $100.00 target price on shares of Janux Therapeutics in a research report on Thursday. Bank of America increased their target price on shares of Janux Therapeutics from $24.00 to $48.00 and gave the stock a “buy” rating in a research report on Wednesday, March 13th. Finally, Wedbush increased their target price on shares of Janux Therapeutics from $53.00 to $74.00 and gave the stock an “outperform” rating in a research report on Wednesday. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $64.83.

Janux Therapeutics Price Performance

Shares of JANX stock opened at $51.94 on Friday. The firm’s 50-day simple moving average is $45.20 and its 200-day simple moving average is $22.38. The firm has a market cap of $2.69 billion, a P/E ratio of -38.76 and a beta of 3.87. Janux Therapeutics has a 1-year low of $5.65 and a 1-year high of $65.60.

Institutional Trading of Janux Therapeutics

Several large investors have recently bought and sold shares of the company. Nisa Investment Advisors LLC grew its position in Janux Therapeutics by 10,740.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,710 shares of the company’s stock valued at $29,000 after acquiring an additional 2,685 shares in the last quarter. Exchange Traded Concepts LLC boosted its stake in shares of Janux Therapeutics by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 14,204 shares of the company’s stock valued at $152,000 after buying an additional 3,602 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Janux Therapeutics by 82.4% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,743 shares of the company’s stock valued at $367,000 after buying an additional 4,400 shares during the last quarter. ProShare Advisors LLC purchased a new position in shares of Janux Therapeutics during the 1st quarter valued at approximately $251,000. Finally, Lester Murray Antman dba SimplyRich purchased a new position in shares of Janux Therapeutics during the 1st quarter valued at approximately $300,000. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.